Form 4: Regeneron EVP Neil Stahl Reports Stock Disposal to Cover Tax Obligations
SEC Form 4
Neil Stahl, EVP of Research and Development at Regeneron Pharmaceuticals, disposed of 304 shares of common stock on December 16, 2024, to cover tax obligations.
Summary
- On December 16, 2024, Neil Stahl, the EVP of Research and Development at Regeneron Pharmaceuticals, disposed of 304 shares of common stock.
- The transaction was executed at a price of $730.81 per share.
- This disposal was related to covering tax obligations.
- Following the transaction, Stahl directly owns 48,829 shares of Regeneron common stock.
- Stahl also indirectly owns 5,849 shares through a 401(k) plan and 4,605 shares through his spouse as trustee.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing relates to a routine stock disposal for tax purposes. It doesn't indicate a significant change in the executive's confidence in the company.
Industry Context
Form 4 filings are standard practice for corporate insiders and are closely watched by investors for insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 12/16/2024 | Date of stock disposal transaction |
| 12/18/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.